NRF2 dysregulation via somatic mutations have also been implicated in ovarian, colon, breast, prostate and gastric cancers [204,205,206,207,208] and, as such, NRF2 inhibitors are being explored as therapeutic options where these signalling pathways have been constitutively activated [209]. Here, NFE2L2 is linked to gastric cancer.